There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.
A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.
A study recently published is suggesting that a key drug target, CDK4/6, regulates a cancer metastasis protein, and may play a role in combating metastasis in triple-negative breast cancer. In addition, this new finding may point to a new way of preventing metastasis in other cancers.
The University of Illinois at Chicago, Northwestern University, the University of Chicago, and other affiliated hospitals and clinics have been selected to enroll 150,000 Illinoisans in the national Precision Medicine Initiative Cohort Program.